{
    "2021-10-25": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Here is What Hedge Funds Think About Novartis AG (NVS)",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Novartis AG",
                        "NVS"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CANOPY-1",
                        "Phase III",
                        "canakinumab",
                        "lung cancer"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}